Physician profile
Randy B Cronic
NPI 1063438679
$1,406.15
in general payments reported to CMS, 2019-2025
30 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.72 · 2020: $94.43 · 2021: $40.57 · 2022: $221 · 2023: $268 · 2024: $285 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $142.96 | 2024-2025 | Rexulti |
| Abbvie INC. | $139.65 | 2022-2025 | Vraylar, Qulipta, Synthroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.43 | 2022-2025 | Xifaxan |
| Pfizer INC. | $102.11 | 2020-2022 | |
| Novo Nordisk INC | $93.36 | 2020-2025 | |
| Corium, LLC | $70.13 | 2023 | Adlarity |
| Tactile Systems Technology INC | $68.83 | 2025 | Flexitouch Plus, Nimbl |
| Lundbeck LLC | $64.14 | 2024-2025 | Rexulti |
| Amgen INC. | $63.59 | 2021-2025 | Repatha, Otezla, Repatha |
| Scilex Pharmaceuticals INC. | $56.72 | 2019 | |
| Exact Sciences Corporation | $56.50 | 2023-2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $44.25 | 2022 | |
| Lilly USA, LLC | $39.38 | 2022-2025 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $34.62 | 2025 | |
| Idorsia Pharmaceuticals US INC | $33.84 | 2023 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.46 | 2024 | Dificid |
| Abbott Laboratories | $20.71 | 2024 | Proclaim |
| Horizon Therapeutics Plc | $20.58 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.41 | 2024 | Fanapt |
| Amarin Pharma, INC. | $20.35 | 2022 | |
| Dexcom, INC. | $19.27 | 2024 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $19.16 | 2025 | Teriparatide, Loreev Xr |
| Glaxosmithkline, LLC. | $18.77 | 2025 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $17.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.41 | 2021 | |
| Esperion Therapeutics, INC. | $15.60 | 2024 | Nexletol |
| Ibsa Pharma INC. | $15.54 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.09 | 2025 | Caplyta |
| Linus Health, INC. | $13.25 | 2023 | |
| Biogen, INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Cronic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.